08048035968
Premium Exporter of Genuine PICLIB 125mg Capsules from India to Singapore – Orchard | Phoenix Exim

1. General Information

PICLIB 125 mg Capsules are an oral anticancer medicine containing Palbociclib. Palbociclib works by inhibiting CDK4 and CDK6, proteins involved in controlling the cell cycle. By inhibiting these proteins, the medicine helps slow the multiplication of certain breast cancer cells.

  • Brand: PICLIB 125 mg
  • Active ingredient: Palbociclib
  • Strength: 125 mg
  • Dosage form: Capsule
  • Therapeutic class: CDK4/6 inhibitor
  • Manufacturer: Hetero Healthcare Ltd.
  • Typical pack: 21 capsules per bottle
  • Prescription: Required

2. Product Information

PICLIB 125 mg contains Palbociclib 125 mg per capsule. The medicine is generally administered as part of a treatment regimen with an aromatase inhibitor, fulvestrant, or—in specific FDA-approved circumstances—in combination with inavolisib and fulvestrant.

The standard starting regimen for palbociclib is 125 mg once daily for 21 consecutive days followed by 7 days without treatment, making a 28-day cycle. Dose interruptions or reductions may be required depending on blood counts, side effects, and individual tolerability.

3. Uses of PICLIB 125 mg

PICLIB 125 mg is used for certain forms of HR-positive, HER2-negative advanced or metastatic breast cancer in adults.

Depending on the patient's treatment plan, palbociclib may be prescribed:

  • With an aromatase inhibitor as endocrine-based therapy.
  • With fulvestrant following progression on endocrine therapy.
  • In certain PIK3CA-mutated, endocrine-resistant breast cancers, with inavolisib and fulvestrant, according to current U.S. labeling.

The exact treatment combination should always be selected by an oncologist.

4. Benefits of PICLIB 125 mg

When appropriately prescribed, PICLIB 125 mg may:

  • Help slow the growth and multiplication of certain breast cancer cells.
  • Help delay progression of HR-positive, HER2-negative advanced or metastatic breast cancer.
  • Provide targeted treatment by inhibiting CDK4/CDK6 activity.
  • Work in combination with hormonal anticancer therapy as part of an individualized treatment plan.

The expected benefit varies according to the cancer type, stage, previous treatment, accompanying medicines, and individual response.

5. Side Effects of PICLIB 125 mg

Like other anticancer medicines, palbociclib can cause side effects. Some can be clinically significant.

Important possible adverse effects include:

  • Neutropenia or reduced white blood cell counts
  • Infections
  • Anemia
  • Thrombocytopenia
  • Fatigue
  • Nausea
  • Diarrhea
  • Hair thinning or hair loss
  • Reduced appetite
  • Rash
  • Stomatitis
  • Liver-related abnormalities
  • Interstitial lung disease/pneumonitis, which can occasionally be serious

Patients should promptly contact their healthcare professional if they develop fever, signs of infection, unusual bleeding, persistent cough, or difficulty breathing.

6. Common Side Effects

Some commonly reported effects include:

  • Tiredness or weakness
  • Low white blood cell count
  • Anemia
  • Nausea
  • Diarrhea
  • Reduced appetite
  • Mouth sores
  • Hair thinning or hair loss
  • Rash
  • Changes in taste

Not everyone experiences these effects, and their severity can vary.

7. How to Use PICLIB 125 mg

PICLIB should be taken exactly as prescribed by the treating oncologist.

The commonly recommended palbociclib regimen is:

125 mg once daily for 21 consecutive days, followed by 7 days off treatment.

Important instructions:

  • Take the capsule orally with food, at approximately the same time each day.
  • Swallow the capsule whole.
  • Do not crush, chew, or open the capsule.
  • Do not independently change the dose or treatment schedule.
  • If a dose is missed or vomiting occurs after taking it, follow the prescribing doctor's instructions rather than taking an extra dose.

8. How PICLIB 125 mg Works

PICLIB contains Palbociclib, which blocks cyclin-dependent kinases 4 and 6 (CDK4/6).

These proteins help regulate progression through the cell cycle. Blocking CDK4/6 interferes with the ability of certain cancer cells to progress through the cell cycle and multiply. This helps slow the growth of HR-positive, HER2-negative breast cancer.

9. Safety Advice

Because PICLIB is a prescription anticancer medicine, medical supervision is essential.

Blood counts: Palbociclib can cause significant neutropenia. Complete blood counts should be monitored before treatment and during treatment as recommended by the oncologist.

Infections: Contact your doctor promptly for fever, chills, or other signs of infection.

Lung problems: Persistent cough, shortness of breath, or difficulty breathing can indicate interstitial lung disease/pneumonitis and requires prompt medical assessment.

Pregnancy: Palbociclib can cause fetal harm. Patients who can become pregnant should discuss effective contraception with their healthcare professional.

Breastfeeding: Breastfeeding should be avoided during palbociclib treatment and for the period recommended by the prescribing information.

Drug interactions: Tell your doctor about all prescription medicines, OTC medicines, supplements, and herbal products because some medicines can affect palbociclib exposure.

Grapefruit: Avoid grapefruit and grapefruit juice unless your healthcare professional specifically advises otherwise, as they can affect palbociclib levels.

10. Frequently Asked Questions

Q1. What is PICLIB 125 mg Capsule used for?
It is used for certain HR-positive, HER2-negative advanced or metastatic breast cancers in adults, generally together with endocrine-based therapy.

Q2. What is the active ingredient in PICLIB 125 mg?
The active ingredient is Palbociclib 125 mg.

Q3. Is PICLIB 125 mg a prescription medicine?
Yes. It should be used under the supervision of a qualified healthcare professional.

Q4. How often is PICLIB 125 mg taken?
The standard starting regimen is once daily for 21 days followed by 7 days off, although the oncologist may modify the regimen according to the patient's condition and tolerability.

Q5. Can I stop PICLIB if I feel better?
No. Do not stop or modify cancer treatment without consulting your oncologist.

Q6. What happens if my white blood cell count becomes low?
Your doctor may monitor your blood counts more frequently, interrupt treatment, or reduce the dose depending on the severity.

Q7. Can PICLIB be taken during pregnancy?
Palbociclib may cause fetal harm and should not be used during pregnancy unless specifically directed by the treating specialist.

Q8. Can PICLIB be taken with grapefruit juice?
Grapefruit and grapefruit juice should generally be avoided because they may affect palbociclib exposure.

11. Substitutes for PICLIB 125 mg

The appropriate substitute should be selected by an oncologist based on the patient's diagnosis, treatment plan, previous therapy, and availability.

Potential palbociclib-based alternatives/brands may include:

  • Ibrance 125 mg Capsules – palbociclib
  • Other locally approved Palbociclib 125 mg products

Other CDK4/6 inhibitors, such as ribociclib or abemaciclib, are not automatic substitutes. They contain different active ingredients and have different prescribing considerations. A doctor should make any substitution.

12. Keywords

Primary keywords:

  • PICLIB 125 mg Capsules
  • PICLIB 125 mg
  • Piclib 125 mg Capsule exporter
  • Piclib 125 mg supplier India
  • Palbociclib 125 mg Capsules
  • Palbociclib 125 mg exporter
  • Palbociclib medicine supplier India
  • Palbociclib breast cancer medicine
  • Palbociclib oncology medicine
  • HR-positive HER2-negative breast cancer medicine

Long-tail B2B/SEO keywords:

  • PICLIB 125 mg Capsules exporter from India
  • PICLIB 125 mg Palbociclib supplier from Nagpur India
  • PICLIB 125 mg Capsules pharmaceutical exporter India
  • Palbociclib 125 mg Capsules wholesale supplier India
  • Palbociclib 125 mg oncology medicine exporter
  • PICLIB 125 mg breast cancer medicine supplier
  • PICLIB 125 mg Capsules international pharmaceutical supplier
  • Palbociclib 125 mg medicine exporter to USA
  • Palbociclib 125 mg medicine exporter to UK
  • Palbociclib 125 mg medicine exporter to Australia
  • Palbociclib 125 mg medicine exporter to Singapore
  • Palbociclib 125 mg medicine exporter to Canada
  • Palbociclib 125 mg medicine exporter to South Korea
  • Palbociclib 125 mg medicine exporter to UAE
  • Genuine PICLIB 125 mg Capsules supplier from India
  • PICLIB 125 mg prescription oncology medicine supplier
  • PICLIB 125 mg CDK4/6 inhibitor supplier
  • Palbociclib 125 mg advanced breast cancer treatment
Aug 20th, 2026 1:42 PM

Keywords